title: [Switching therapy from natalizumab to fingolimod: reduction of the washout time?].
authors.affiliation: Servicio de Farmacia Hospital Virgen de la Luz, Gerencia Atención Integrada de Cuenca.. jsgundin@sescam.jccm.es.
authors.forename: Julia
authors.initials: J
authors.lastname: Sánchez-Gundín
authors.affiliation: Servicio de Farmacia Hospital Virgen de la Luz, Gerencia Atención Integrada de Cuenca.. jsgundin@sescam.jccm.es.
authors.forename: Amparo
authors.initials: A
authors.lastname: Flor García
authors.affiliation: Servicio de Farmacia Hospital Virgen de la Luz, Gerencia Atención Integrada de Cuenca.. jsgundin@sescam.jccm.es.
authors.forename: Caridad
authors.initials: C
authors.lastname: Martí Gil
authors.affiliation: Servicio de Neurología Hospital Virgen de la Luz, Gerencia Atención Integrada de Cuenca. España.. jsgundin@sescam.jccm.es.
authors.forename: Lourdes
authors.initials: L
authors.lastname: Gómez Romero
mesh_terms: D000328:Adult; D005260:Female; D000068876:Fingolimod Hydrochloride / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000000981:diagnostic imaging / Q000188:drug therapy*; D000069442:Natalizumab / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D007166:Immunosuppressive Agents; D000069442:Natalizumab; D000068876:Fingolimod Hydrochloride